Ibrexafungerp Citrate
FDA-approved product (tablet, oral), marketed as Brexafemme.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Vulvovaginal candidiasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ibrexafungerp Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease51.7% AI-predicted activityagainst MRSA50+ registered studies
- Ergotamine TartrateExisting use: Headache, Migraine disorder51.7% AI-predicted activityagainst MRSA10 registered studies
- LubiprostoneExisting use: Chronic pain, Constipation, Constipation disorder and 1 more51.7% AI-predicted activityagainst MRSA50+ registered studies
- Testosterone EnanthateExisting use: Cancer, Hypogonadism, Hypogonadotropic hypogonadism and 5 more51.7% AI-predicted activityagainst MRSA50+ registered studies
- Testosterone UndecanoateExisting use: Cancer, Hypogonadism, Hypogonadotropic hypogonadism and 5 more51.7% AI-predicted activityagainst MRSA50+ registered studies
- Tenapanor HydrochlorideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome51.6% AI-predicted activityagainst MRSA2 registered studies
- LusutrombopagExisting use: Hemorrhage, Thrombocytopenia51.6% AI-predicted activityagainst MRSA8 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more51.5% AI-predicted activityagainst MRSA50+ registered studies
- Etoposide PhosphateExisting use: Cancer, Lung cancer, Lung neoplasm and 3 more51.5% AI-predicted activityagainst MRSA50+ registered studies
- CholecalciferolExisting use: Anemia (phenotype), Iron deficiency anemia, Osteoporosis51.5% AI-predicted activityagainst MRSA50+ registered studies
- LifitegrastExisting use: Dry eye syndrome, Eye disease51.5% AI-predicted activityagainst MRSA39 registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells51.4% AI-predicted activityagainst MRSA10 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.